论文部分内容阅读
目的探讨精准肝切除联合术中灌注化疗在原发性肝癌治疗中的安全性和有效性。方法选取2008年2月-2010年2月原发性肝癌行手术治疗的患者80例。随机均分为观察组和对照组各40例。观察组予精准肝切除联合术中灌注化疗,对照组则采用常规肝切除术。比较2组手术时间,术中失血量,术后24h血丙氨酸转氨酶(ALT)及天冬氨酸转氨酶(AST)水平,手术病死率,住院时间,术后1、3年复发率及生存率。结果观察组手术时间长于对照组,术中失血量少于对照组,术后1年、3年复发率低于对照组,术后1年、3年生存率高于对照组,差异均有统计学意义(P均<0.05);2组术后24h血ALT及AST水平、手术病死率、住院时间比较差异均无统计学意义(P均>0.05)。结论精准肝切除联合术中灌注化疗治疗原发性肝癌安全、有效。
Objective To investigate the safety and efficacy of precision hepatectomy combined with intraoperative perfusion chemotherapy in the treatment of primary liver cancer. Methods Eighty patients with surgical treatment of primary liver cancer from February 2008 to February 2010 were selected. Randomly divided into observation group and control group of 40 cases. The observation group was treated with precision hepatectomy and intraoperative chemotherapy, while the control group was treated by conventional hepatectomy. The operation time, intraoperative blood loss, ALT and AST levels, operative mortality, length of hospital stay, postoperative 1-3 years recurrence and survival were compared between the two groups rate. Results The operation time of the observation group was longer than that of the control group. The intraoperative blood loss was less than that of the control group. The recurrence rates at 1 year and 3 years after operation were lower than those in the control group. The 1-year and 3-year survival rates were higher in the observation group than in the control group (P <0.05). There was no significant difference in ALT and AST levels, operative mortality and length of hospital stay between the two groups (all P> 0.05). Conclusions Precision hepatectomy combined with intraoperative chemotherapy in the treatment of primary liver cancer is safe and effective.